Clinical Trials Logo

Anxiety Disorders clinical trials

View clinical trials related to Anxiety Disorders.

Filter by:

NCT ID: NCT00616655 Completed - Clinical trials for Generalized Anxiety Disorder

Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects

Start date: January 2008
Phase: Phase 2
Study type: Interventional

To determine the safety and efficacy of SEP-225441 (eszopiclone) in subjects with generalized anxiety disorder (GAD).

NCT ID: NCT00616447 Completed - Clinical trials for Generalized Anxiety Disorder

rTMS Treatment in Patients With General Anxiety Disorder

Start date: January 2008
Phase: N/A
Study type: Interventional

This study will compare the change detected by a standardized rating scale (Hamilton Anxiety Rating Scale) scores in the active treatment group as compared to sham (placebo) group after 6 weeks of rTMS treatments. It is hoped that 6 weeks of rTMS treatment will lead to improvement of core symptoms in patients with GAD.

NCT ID: NCT00613067 Completed - Clinical trials for Generalized Anxiety Disorder

ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder

N1
Start date: December 2007
Phase: N/A
Study type: Interventional

Amplitude changes of the N1 and the N1/P2 ERP component in response to different tone intensities have been suggested as a correlative of central serotonergic activity. A strong loudness dependence amplitude increase (strong intensity dependence) reflects low serotonergic neurotransmission and vice versa. Many researchers assumed that the brain serotonergic activity could influence treatment response of highly selective serotonin reuptake inhibitors in depression and anxiety disorders. There are a couple of studies reporting associations of N1 amplitude intensity dependence with response to Citalopram (positive correlation) and Reboxetine (negative correlation) treatment in major depressive disorder patients. But so far there have been no reports about associations between ERP N1 and antidepressant response in GAD patients. So, it would be very interesting to explore the correlations between ERP N1 amplitude change and the Escitalopram treatment responsiveness in GAD patients.

NCT ID: NCT00612859 Completed - Anxiety Disorders Clinical Trials

Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)

Start date: September 2003
Phase: Phase 2
Study type: Interventional

Preclinical and clinical findings indicate that LEV has some anxiolytic potential. There is reason to believe that compounds with anxiolytic activity may have broad clinical utility across the anxiety spectrum. This trial was intended to explore LEV's utility in adults with social anxiety disorder.

NCT ID: NCT00606541 Terminated - Clinical trials for Social Anxiety Disorder

An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)

Start date: January 2008
Phase: Phase 0
Study type: Interventional

Purpose of Study: To examine 1) the short and long-term effectiveness and tolerability of quetiapine (extended release) XR for the treatment of social anxiety disorder (SAD); and 2) continuation effects of quetiapine XR in preventing SAD relapse.

NCT ID: NCT00602563 Completed - Clinical trials for Generalized Anxiety Disorder

Attention Training for Generalized Anxiety Disorder

Start date: December 2007
Phase: N/A
Study type: Interventional

Generalized Anxiety Disorder (GAD) has high prelevance (up to 8.5%; Roy-Byrne & Wagner, 2004) and leads to functional impairment (Wittchen et al., 2002; Ballenger et al., 2001). Researchers have demonstrated a relationship between attention bias to threatening information and GAD. However, this knowledge has not yet been translated into effective treatments. The goal of this project is develop and test a new computerized treatment for Generalized Anxiety Disorder.

NCT ID: NCT00602212 Completed - Clinical trials for Generalized Anxiety Disorder

Virtual Reality as Anxiety Management Tool for Generalized Anxiety Disorder

INTREPID
Start date: February 2008
Phase: N/A
Study type: Interventional

Generalized Anxiety Disorder (GAD) is a psychiatric disease characterized by long-lasting anxiety that is not focused on a specific object or situation. According to the DSM-IV-TR the essential feature of GAD is at least six months of "excessive anxiety and worry" about a variety of events and situations. Anxiety and worry are often accompanied by a variety of physical symptoms like restlessness, being easily fatigued, difficulty concentrating, irritability, muscle tension and disturbed sleep. The high prevalence of GAD in the general population and the severe limitations it causes point out the necessity to find new strategies to treat it in a more efficient way. Within the treatment of GAD, physical (relaxation and controlled breathing), behavioral (visualization and controlled exposure) and cognitive control strategies (challenging negative thoughts) represent a key part of the treatment, even if they are hard to be learned. Given the features of this disease and its pervasive effect on patient's personal, occupational and affective life, we thought it could benefit from an ubiquitous treatment.We suggested, then, to improve the treatment of GAD through the use of a biofeedback enhanced virtual reality (VR) system used for relaxation, controlled exposure and SIT. The use of SIT in the context of GAD is motivated by the acknowledgment that sometimes stressors can't be avoided or altered and then patients can't apply strategies focused on finding solutions. In these instances, coping effort should be directed to emotionally palliative set of responses such as acceptance, reframing and perspective thinking. All these cognitive changes are facilitated if a concomitant relaxation is induced. The treatment involves two virtual reality components: I) an immersive virtual reality system experienced in the therapist's office; II) a mobile exposure system allowing patients to perform the virtual experience in an outpatient setting. The role of the mobile exposure system is the following: - To present and structure emotionally relevant contents in an ubiquitous context. - To verify the compliance of the patient and eventually alert patient/therapist; - To track in real-time the emotional level of the patient and record it for later assessment by the therapist; - To provide a feedback to the patient able to help him in coping with the contents; - To automatically contact the therapist if the emotional level is higher than a preset cut-off value defined by the therapist.

NCT ID: NCT00601965 Completed - Clinical trials for Generalized Anxiety Disorder

Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults

Start date: October 2007
Phase: N/A
Study type: Interventional

This study will assess whether adding cognitive behavioral therapy to the antidepressant escitalopram is effective in reducing anxiety in older adults with generalized anxiety disorder.

NCT ID: NCT00599742 Recruiting - Anxiety Clinical Trials

Comorbidity Between Balance and Childhood Anxiety

Start date: December 2007
Phase: N/A
Study type: Interventional

Previous studies report frequent comorbidity of anxiety and sensory-motor imbalance in adults (Sklare et al., 2001). Only a few studies tested the comorbidity in children. We confirmed that: a) children with primary diagnosis of poor balance demonstrate an elevated anxiety level (Brat et al., 2006, submitted) and, b) children with primary diagnosis of generalized anxiety disorder demonstrate poor balance performance (Erez et al., 2004). These studies demonstrate the presence of balance-anxiety comorbidity in children with primary disorder of either balance or anxiety. Our theoretical reasoning formalized under the "three stage theory of learning" points to the possibility that poor balance may either predispose or cause the emergence of anxiety disorder (Erez et al., 2004). Thus, in the present study we test two predictions: (a) high prevalence of comorbidity of anxiety and balance disorders in children with a primary diagnosis of generalized or separation anxiety disorder, and, (b) intensive balance training, but not training of flexibility and power, will reduce the level of anxiety in children with primary diagnosis of anxiety.

NCT ID: NCT00596284 Completed - Dementia Clinical Trials

Cognitive Behavior Therapy for Treating Anxiety in People With Dementia

Start date: January 2008
Phase: Phase 1
Study type: Interventional

This study will evaluate the effectiveness of cognitive behavioral therapy in treating anxiety in older adults with dementia.